

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 December 2022 (29.12.2022)



(10) International Publication Number
WO 2022/272153 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) C07K 14/54 (2006.01)
A61K 39/395 (2006.01) C07K 14/705 (2006.01)

7000 Marina Boulevard, Brisbane, California 94005 (US).
GERTNER-DARDENNE, Julie; c/o Sangamo Therapeutics, Inc., 7000 Marina Boulevard, Brisbane, California 94005 (US).

(21) International Application Number:

PCT/US2022/035028

(74) Agent: **LI, Z. Ying** et al.; 1330 Connecticut Avenue, N.W., Washington, District of Columbia 20036 (US).

(22) International Filing Date:

24 June 2022 (24.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

21181801.8 25 June 2021 (25.06.2021) EP
63/214,950 25 June 2021 (25.06.2021) US

(71) Applicant: **SANGAMO THERAPEUTICS, INC.**
[US/US]; 7000 Marina Boulevard, Brisbane, California 94005 (US).

(72) Inventors: **ABEL, Tobias**; c/o Sangamo Therapeutics, Inc., 7000 Marina Boulevard, Brisbane, California 94005 (US). **DE LA ROSA, Maurus**; c/o Sangamo Therapeutics, Inc., 7000 Marina Boulevard, Brisbane, California 94005 (US). **FENARD, David**; c/o Sangamo Therapeutics, Inc.,

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: ANTIGEN BINDERS SPECIFIC FOR IL-23R AND USES THEREOF

	scFv	Linker	Trans Membrane Domain	Signaling Domain	
CAR#1	hmIL23R (14-11-D07)	CD8 linker	CD8 TM	CD28	CD3Z
CAR#2	hmIL23R (IL23RLamS4-G3)	CD8 linker	CD8 TM	CD28	CD3Z

FIG. 1

(57) Abstract: IL23R overexpression has been described as a common feature of pathogenic inflammatory cells involved in the onset and maintenance of autoimmune diseases and chronic inflammation. The present disclosure relates to a novel antigen binder directed to IL-23R, to compositions that comprise said antigen binder, and to the use of said antigen binder. The present disclosure further relates to fusion proteins comprising said antigen binder, such as, for example, chimeric antigen receptors.

[Continued on next page]



WO 2022/272153 A1

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*